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Abstract
Background: For a randomized trial, the primary publication is usually the one which reports the results of the
primary outcome and provides consolidated data from all study centers. Other aspects of a randomized trial’s
findings (that is, non-primary results) are often reported in subsequent publications.
Methods: We carried out a cross-sectional review of the characteristics and type of information reported in
non-primary reports (n = 69) of randomized trials (indexed in PubMed core clinical journals in 2009) and whether
they report pre-specified or exploratory analyses. We also compared consistency of information in non-primary
publications with that reported in the primary publication.
Results: The majority (n = 56; 81%) of non-primary publications were large, multicenter trials, published in
specialty journals. Most reported subgroup analyses (n = 27; 39%), analyzing a specific subgroup of patients
from the randomized trial, or reported on secondary outcomes (n = 29; 42%); 19% (n = 13) reported extended
follow-up. Less than half reported details of trial registration (n = 30; 43%) or the trial protocol (n = 27; 39%) and
in 41% (n = 28) it was unclear from reading the abstract that the report was not the primary publication for the
trial. Non-primary publications often analyzed and reported multiple different outcomes (16% reported >20
outcomes) and in 10% (n = 7) it was unclear how many outcomes had actually been assessed; in 42% (n = 29) it
was unclear whether the analyses reported were pre-specified or exploratory. Only 39% (n = 27) of non-primary
publications described the primary outcome of the randomized trial, 6% (n = 4) reported its numerical results
and 9% (n = 6) details of how participants were randomized.
Conclusion: Non-primary publications often lack important information about the randomized trial and the type
of analyses conducted and whether these were pre-specified or exploratory to enable readers to accurately
identify and assess the validity and reliably of the study findings. We provide recommendations for what
information authors should include in non-primary reports of randomized trials.
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Background
The Good Publication Practice for communicating com-
pany sponsored medical research (GPP2) guidelines [1]
define a primary publication as the first full report of a
study. For a randomized trial, the primary publication is
the one which reports the results of the primary out-
come (that is, the outcome used to determine the design
and estimate the sample size of the randomized trial)
and provides consolidated data from all study centers
[2]. Additional findings from a randomized trial (that
is, non-primary results) are frequently reported in sub-
sequent publications. We refer to these types of publi-
cation as non-primary publications and might include
pre-specified or exploratory subgroup analyses, perhaps
analyzing only a specific subgroup of patients from the
randomized trial, secondary outcomes, health economic
analyses, or the patient outcomes after an extended
period of follow-up [1,3]. Such publications are also
sometimes referred to as secondary publications; however,
this term can be misleading as it can be used to refer to
summaries of existing studies or publications in other
languages [4].
Readers of non-primary publications of randomized
trials should be able to interpret the findings of these
new analyses within the context of the previously pub-
lished main results. However, there is limited evidence
on how non-primary publications are reported in the
literature or whether this might be improved [5]. In this
study we describe the characteristics of a representative
sample of published non-primary reports of randomized
trials and assess the extent to which such publications
report pre-specified or exploratory analyses. We also
compared the trial information reported in non-primary
publication with that reported in the full text of the
corresponding primary publication.
Methods
Sample
We searched PubMed for all reports of randomized tri-
als indexed from 1 July to 31 December 2009 with the
publication type ‘Randomized Controlled Trial’ (search
as of 4 January 2010). We limited our search to the Na-
tional Library of Medicine’s (NLM) set of 121 Core
Clinical Journals (formerly published as the Abridged
Index Medicus), all of which are published in English.
Eligibility criteria
We included all non-primary reports of randomized trials,
which reported a comparison between patient groups.
This comparison could be between intervention groups
as randomized, as in the primary trial publication, or
between groups not randomized, such as a comparison
between patient subgroups, perhaps across interventions.
We defined a non-primary publication as one, which
reported trial results other than the primary trial publi-
cation (that is, the first publication with consolidated
data from all centers, including the results for the primary
outcome). We excluded non-primary reports of random-
ized trials that did not include a comparative analysis
(for example, those exploring risk factors in a particular
patient group) and those which reported early phase
trials (for example, pilot and feasibility studies), trial
protocols, or interim analyses.
Screening process
One person (SH) screened the titles and abstracts of all
retrieved reports to exclude any obvious reports of
non-randomized studies. A copy of the full article was
then obtained for all remaining records and two people
assessed and confirmed whether or not they met the
eligibility criteria. Any additional material about the
trial included as an appendix on the journal website
was also obtained if available.
Data extraction
Data extraction was carried out by six reviewers working
in pairs (in blocks of 25 articles allocated at random).
Each reviewer independently extracted data from eligible
reports; any differences between reviewers in a pair
were resolved by discussion, with the involvement of an
arbitrator if necessary. To ensure consistency between
reviewers, we piloted the data extraction form using a
sample of five papers from the sample under review. A
data extraction manual was developed to provide guidance
for each item on the data extraction form. Following
piloting of the data extraction form the data extraction
manual was modified slightly to ensure consistency in
the data extraction process.
We extracted information on whether the comparison
between treatment or patients groups was randomized,
the journal type, source of funding, details of trial regis-
tration, reference to the trial protocol, whether the
study was referred to as a non-primary publication in
the abstract, the disease area and the type of intervention
being investigated. We assessed the following study
specific characteristics in relation to the non-primary
publication: the number of study centers, the number
of study groups, total sample size, and whether the
non-primary publication analyzed all, or a subset of,
randomized participants. We extracted data on the
number of outcomes (where there was a comparison
group) reported in the non-primary publication and,
for the outcome which was the main focus of the non-
primary publication, whether it was pre-specified or ex-
ploratory, the statistical methods used, how the results
were reported and whether they were statistically sig-
nificant. If more than one main outcome was reported
we selected the one reported first in the methods section,
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but if not reported there we took the first outcome
reported in the results section. We defined an outcome
as a variable intended for comparison between groups; any
outcomes assessed at multiple time points were classified
as separate outcomes [6]. We also assessed the extent to
which the non-primary publication reported information
about the primary trial publication that reported the main
results of the trial. Where non-primary publications pro-
vided a citation (or other unique identifier) to the primary
publication of the trial, we compared the consistency of
information reported in the two publications.
Data analysis
All analyses were descriptive. The primary analysis focused
on the general characteristics of the non-primary publica-
tion and the reporting of their study outcomes and results.
We compared reporting between non-primary publications
where the comparison between groups was or was not as
randomized. We also compared the consistency of trial in-
formation reported in non-primary publications with that
reported in the full text of the primary publication.
Results
The PubMed publication type search term ‘Randomized
Controlled Trial’ identified 644 possible reports of ran-
domized trials in the specified time window. After screen-
ing the titles and abstracts of all retrieved citations, we
reviewed 591 full text articles (see Figure 1 for reasons for
exclusion) resulting in 85 reports of non-primary publica-
tions; 16 were excluded as they did not include a compari-
son group. This resulted in 69 reports of non-primary
publications; in 42 (61%) the comparison between groups
was as randomized and in 27 (39%) the comparison was
not as randomized. If a publication reported both types
of comparison then we selected the one where the
comparison between groups was as randomized.
General characteristics of the non-primary publications
Table 1 provides information on the general characteris-
tics of the non-primary publications. The majority (n =
56; 81%) of reports were published in specialty journals
with by far the most common medical area being cardi-
ology (n = 35; 51%). Forty-five percent (n = 31) of non-
Figure 1 Identification of non-primary publication from PubMed citations indexed from July to December 2009.
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primary publication reports were non-industry funded,
25% (n = 17) were part industry funded and 14% (n =
14) were solely industry funded. Around half (n = 35;
51%) of the reports investigated drugs as the primary
intervention of interest, whereas 32% (n = 22) assessed
surgical or procedural interventions and 16% (n = 11)
assessed counseling or lifestyle interventions. Details of
trial registration (n = 30; 43%) or where the trial protocol
(n = 27; 39%) could be accessed were each reported in less
than half of non-primary publication reports. The majority
(n = 56; 81%) of trials were described as multicenter, and
most had two study groups (n = 55; 80%).
Overall most non-primary publications reported on
either subgroup analyses (n = 27; 39%), analyzing a spe-
cific subgroup of patients from the randomized trial, or
reported on secondary outcomes (n = 29; 42%); 19% (n =
13) reported outcomes during extended follow-up periods
(see Additional file 1 for more detail on the types of study
identified). Non-primary publications where the com-
parison between groups was as randomized were more
likely to report analyses of secondary outcomes (n = 19;
Table 1 General characteristics of the non-primary
publication
Total
(n = 69)
Comparison as
randomized (n = 42)
Comparison not as
randomized (n = 27)
Journal type
Specialty 56 (81%) 30 (71%) 26 (96%)
General 13 (19%) 12 (29%) 1 (4%)
Funding source
Solely industry 14 (20%) 9 (21%) 5 (18.5%)
Part
industry
17 (25%) 12 (29%) 5 (18.5%)
Non-
industry
31 (45%) 18 (43%) 13 (48%)
Unknown 7 (10%) 3 (7%) 4 (15%)
Trial registration
Reported 30 (43%) 22 (52%) 8 (30%)
Not
reported
39 (57%) 20 (48%) 19 (70%)
Trial protocol
Reported 27 (39%) 17 (40%) 10 (37%)
Not
reported
42 (61%) 25 (60%) 17 (63%)
Common disease specialties
Cardiology 35 (51%) 16 (38%) 19 (70%)
Infectious
diseases
3 (4%) 2 (5%) 1 (4%)
Rheumatology
3 (4%) 3 (7%) 0
Neurology 2 (3%) 1 (2%) 1 (4%)
Surgery 2 (3%) 1 (2%) 1 (4%)
Type of intervention
Drug 35 (51%) 21 (50%) 14 (52%)
Surgery/
procedure
22 (32%) 16 (38%) 6 (22%)
Counseling/
lifestyle
11 (16%) 5 (12%) 6 (22%)
Equipment 1 (1%) 0 1 (4%)
Study centers
Single 1 (2%) 0 1 (4%)
Multiple 56 (81%) 35 (83%) 21 (78%)
Unclear 12 (17%) 7 (17%) 5 (18%)
Main focus of non-primary publication
Subgroup
analyses
27 (39%) 11 (26%) 16 (60%)
Secondary
outcomes
29 (42%) 19 (45%) 10 (37%)
Extended
follow-up
13 (19%) 12 (27%) 1 (4%)
Time period assessed
Reported 39 (57%) 23 (55%) 16 (59%)
Table 1 General characteristics of the non-primary
publication (Continued)
Total
(n = 69)
Comparison as
randomized (n = 42)
Comparison not as
randomized (n = 27)
Not
reported
30 (43%) 19 (45%) 11 (41%)
Number of study groups in non-primary publication
2 55 (80%) 33 (79%) 22 (82%)
3 10 (14%) 8 (19%) 2 (7%)
4 3 (4%) 1 (2%) 2 (7%)
≥5 1 (2%) 0 1 (4%)
Number of patients randomized in non-primary publication
Median
(IQR)
1,003
(347 to
2,699)
762 (256 to 2,659) 1,348 (660 to 2,928)
Range 34 to 20,479
34 to
21,906
36 to 21,906
Non-primary publication analyzed all randomized participants
Yes 28 (40%) 20 (48%) 8 (30%)
No 33 (48%) 17 (40%) 16 (59%)
Unclear 8 (12%) 5 (12%) 3 (11%)
Flow diagram reported
Yes 17 (25%) 9 (21%) 8 (30%)
No 52 (75%) 33 (79%) 19 (70%)
Identified as non-primary publication in the abstracta
Yes 40 (59%) 23 (56%) 17 (63%)
No 28 (41%) 18 (44%) 10 (37%)
aIdentified as non-primary in the abstract: publication did not have an abstract
(n = 1).
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45%), whereas non-primary publications where the com-
parison was not as randomized were more likely to report
on subgroup analyses or a specific subset of patients
(n = 16; 60%).
Reporting of non-primary publication study outcomes
and results
Table 2 provides information of the type of outcomes
and results reported in the non-primary publication.
Just under half (n = 29; 42%) of non-primary publica-
tions reported between one and five different outcomes
(where there was a comparison group), with 16% (n =
11) reporting >11 different outcomes and 16% (n = 11)
reporting >20; poor reporting meant that the number
of outcomes assessed was sometimes unclear (n = 7;
10%). It was also often unclear (n = 29; 42%) whether
the analyses described in the non-primary publication
were pre-specified (that is, planned and documented
before examination of the data preferably in the study
protocol) or exploratory (that is, the hypothesis being
tested was not specified before examination of the data).
However, the majority of non-primary publications did
provide sufficient information on the statistical methods
(n = 68; 98%) used to compare groups and reported a
summary results for the main outcome of the non-
primary publication (n = 66; 96%) with estimated effect
sizes and precision (n = 52; 75%); in 64% (n = 44) the re-
sults for the main outcome were statistically significant.
Reporting of information about the primary publication
It was unclear from reading the abstract in 41% (n = 28)
of non-primary publications that it did not report the
main results of the trial. Half (n = 33; 48%) of non-
primary publications cited only the primary trial report,
if additional publications were cited this usually related
to the study protocol (n = 19; 27%); five only cited the
trial protocol despite the main results of the trial having
already been published (Table 3). Less than half (n = 27;
39%) of non-primary publications reported the main
outcome of the trial (that is, that reported in the primary
publication) with only 6% (n = 4) reporting its numerical
results and only 9% (n = 6) reporting on the method of
randomization.
Comparison of information between the non-primary
and primary publication
Finally, we compared the information reported in the
non-primary publication with that reported in the primary
publication (Table 4). The majority (n = 56; 81%) of non-
primary publications were published in specialty journals
whereas most (n = 46; 68%) primary publications were
published in general medical journals, with one-quarter
(n = 16; 23%) having the same corresponding author in
both publications. Non-primary publications were more
Table 2 Reporting of non-primary publication study
outcomes and results
Overall
(n = 69)
Comparison as
randomized (n = 42)
Comparison not as
randomized (n = 27)
Number of outcomes reported in non-primary publicationa
1 to 5 29 (42%) 20 (48%) 9 (33%)
6 to 10 11 (16%) 5 (12%) 6 (22%)
11 to 20 11 (16%) 6 (14%) 5 (19%)
>20 11 (16%) 8 (19%) 3 (11%)
Unclear 7 (10%) 3 (7%) 4 (15%)
Outcomes reported in non-primary publication
Pre-
specified
22 (32%) 16 (38%) 6 (22%)
Exploratory 10 (15%) 7 (17%) 3 (11%)
Pre-
specified and
exploratory
5 (7%) 2 (5%) 3 (11%)
32 (46%) 17 (40%) 15 (56%)
Unclear
Analysis for main outcome of non-primary publication
Pre-
specified (in
publication)
16 (23%) 12 (28.5%) 4 (15%)
5 (7%) 5 (12%) 0
Pre-
specified (in
register)
19 (28%) 13 (31%) 6 (22%)
Exploratory 29 (42%) 12 (28.5%) 17 (63%)
Unclear
Statistical methods used to compare groups for main outcome of non-
primary publication
Reported 68 (98%) 42 (100%) 26 (96%)
Not
reported
1 (2%) 0 1 (4%)
Summary result for each group for main outcome of non-primary
publication
Reported 66 (96%) 40 (95%) 26 (96%)
Not
reported
3 (4%) 2 (5%) 1 (4%)
Estimated effect size and precision of effect estimate for main outcome
of non-primary publication
Reported 52 (75%) 32 (76%) 20 (74%)
Not
reported
17 (25%) 10 (24%) 7 (26%)
Results statistically significant for main outcome of non-primary
publication
Yes 44 (64%) 23 (55%) 21 (78%)
No 21 (30%) 15 (35%) 6 (22%)
Unclear 2 (3%) 2 (5%) 0
Not
reported
2 (3%) 2 (5%) 0
aFor which there was a comparison between groups.
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likely to report being non-industry funded (Non-primary:
45% versus Primary: 36%) whereas primary publications
were more likely to report being solely (20% versus 30%)
or partially industry funded (25% versus 33%). The source
of funding was the same in both the non-primary and
primary publication 65% (n = 45) of the time. In seven
publications, the source of funding was reported in the
primary publication (solely industry funded n = 4; non-
industry funded n = 3) but omitted from the non-primary
publication. Less than half of non-primary and primary
publications reported details of trial registration or where
the trial protocol could be accessed.
Most primary publications (n = 64; 93%) reported the
time period in which the trial was conducted compared to
around half of non-primary publications (n = 39; 57%).
The median number of participants randomized in the
primary publication was 1,452 (IQR 389 to 4,439, range 34
to 21,906). Only around one-third of publications (n = 26;
38%), reported the same number of participants in both
the non-primary and primary publication. Just over half
(n = 37; 53%) of primary publications reported a
statistically significant result for main outcome of the trial.
Interestingly, of the primary publications which reported a
non-statistically significant result for the main outcome of
the trial (n = 31; 45%), just over half (n = 17/31; 55%)
reported the main outcome of the non-primary publica-
tion as being statistically significant.
Discussion
Summary of main findings
Our study provides an overview of the information cur-
rently reported in non-primary reports of randomized
trials published in the scientific literature, the type of
analyses they perform, and the extent to which they
report information about the main outcome of the ran-
domized trial and its results. The majority (n = 56; 81%)
Table 3 Information about the primary publication
reported in the non-primary publication
Overall
(n = 69)
Comparison as
randomized (n = 42)
Comparison not as
randomized (n = 27)
Number of citations relating to primary publication
Cites
protocol onlya
6 (9%) 1 (2%) 5 (19%)
Cites
primary
publication
only
33 (48%) 21 (50%) 12 (44%)
Cites
protocol and
primary
publication
19 (27%) 12 (29%) 7 (26%)
Cites
multiple
publications
11 (16%) 8 (19%) 3 (11%)
Identified main outcome of primary publication
Reported 27 (39%) 20 (48%) 7 (26%)
Not
reported
42 (61%) 22 (52%) 20 (74%)
Numerical results reported for main outcome of primary publication
Reported 4 (6%) 4 (10%) 0
Not
reported
65 (94%) 38 (90%) 27 (100%)
Method of randomization
Reported 6 (9%) 4 (10%) 2 (7%)
Not
reported
63 (91%) 38 (90%) 25 (93%)
aNumber of citations relating to primary publication: primary publication not
published at time of non-primary publication (n = 1).
Table 4 Comparison of information between the
non-primary and primary publication
Non-primary publication
(n = 69)
Primary publication
(n = 69)
Journal type
Specialty 56 (81%) 22 (32%)
General 13 (19%) 47 (68%)
Funding source
Solely industry 14 (20%) 21 (30%)
Part industry 17 (25%) 23 (33%)
Non industry 31 (45%) 25 (36%)
Unknown 7 (10%) 0
Trial registration
Reported 30 (43%) 32 (46%)
Not reported 39 (57%) 37 (54%)
Trial protocol
Reported 27 (39%) 26 (38%)
Not reported 42 (61%) 43 (62%)
Study centers
Single 1 (2%) 3 (4%)
Multiple 56 (81%) 64 (93%)
Unclear 12 (17%) 2 (3%)
Time period assessed
Reported 39 (57%) 64 (93%)
Not reported 30 (43%) 5 (7%)
Number of study groups
2 55 (80%) 54 (78%)
3 10 (14%) 12 (17%)
4 3 (4%) 2 (3%)
≥5 1 (2%) 1 (2%)
Number of patients randomized
Median (IQR) 1,003 (347 to 2,699) 1,452 (389 to 4,439)
Range 34 to 21,906 34 to 21,906
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of non-primary publications were large, multicenter trials,
published in specialty journals. Most reported on either
subgroup analyses, analyzing a specific subgroup of pa-
tients from the randomized trial, or reported on secondary
outcomes or analyses; a small number reported evaluating
primary outcomes during extended follow-up periods.
Less than half of non-primary publications reported de-
tails of trial registration, where the trial protocol could
be accessed, or made it clear in the abstract that the
report was not the primary publication for the trial. This
could be misleading and make it difficult, or in some cases
impossible, to identify multiple publications for the same
trial [5,7].
Non-primary publications often reported results for mul-
tiple outcomes. It was frequently unclear, however, how
many outcomes had actually been assessed or whether the
analyses described in the non-primary publication were
pre-specified or post-hoc exploratory analyses. Multiple
testing, for example by performing multiple subgroup
analysis, can be a problem because of the risk of false
positive findings the more analyses that are performed
[3,8]. This could be a particular problem for post-hoc
analysis where it is often unclear how many analyses
were undertaken and whether they were motivated by
inspection of the data [9-11]. An investigator might
also be tempted to ‘fish’ for, and selectively report, the
results of statistically significant outcomes as opposed
to non-significant outcomes [12]; thus one should be
cautious in the interpretation of such results [13,14].
There is some indication of selective reporting in our
study whereby primary publications, which reported a
non-statistically significant result for the main outcome
of the trial, were more likely to report the main outcome
of the non-primary publication as being statistically
significant.
Readers of non-primary publications of randomized
trials should be able to interpret the findings of these
new analyses in the context of the previously published
main results. Authors should therefore provide sufficient
details about the study methods, sample selection, the
primary outcome, and its results to enable readers to as-
sess the new findings [15]. However, in our sample less
than half of non-primary publications reported the main
outcome of the randomized trial, with very few reporting
its numerical results.
Comparison with other studies
We are not aware of other similar studies assessing the
characteristics of and types of analyses reported in non-
primary reports of randomized trials. However, several
studies have examined the reporting of subgroup analyses
published in primary reports of randomized trials (that
is, reporting the primary outcome) and have identified
similar shortcomings [9,11,16-18]. For example, Wang
and colleagues [11] reviewed 97 primary reports of ran-
domized trials published in the New England Journal of
Medicine between 2005 and 2006; 59 (61%) reported
subgroup analyses, with larger trials and multicenter
trials being more likely to report subgroup analyses
than smaller trials and single-center trials. Among the
trials which reported subgroup analyses, only 21 (36%)
mentioned these analyses in the methods section and in
40 (68%) it was unclear whether the subgroup analyses
were pre-specified or exploratory. Assmann [9] reported
similar findings in a review of 50 trials published in 1997
in four leading medical journals, as did Hernandez and
Table 5 Recommendations for information to include in non-primary reports of randomized trialsa
Item Description
Abstract Objectives of this report, and whether analyses were pre-specified or exploratory. A statement that it is not the primary trial report
Objectives Specific objectives or hypothesis of this report (for example, subgroup analyses, secondary outcomes, extended follow-up)
Methods Set in context of main trial and its results, cite primary trial report, describe method of randomization, details of blinding (if done),
completeness of follow-up, identify primary outcome, and summarize numerical results
Outcomes Number and type of outcomes assessed in this report, and how and when measured. Whether outcomes were pre-specified or
exploratory
Statistical
methods
Statistical methods used to compare groups in this report
Participants Number of intervention groups and whether this report includes all groups
Number of participants randomized to each group and whether analyzed all randomized participants
Results For each outcome a summary result and sample size for each group and the estimated effect size (for example, relative risk) and
its precision
Other
information
Registration number and name of trial registry
Where the full trial protocol can be accessed, if available
Sources of funding and other support (such as supply of drugs), role of funder
aAdapted from 2010 CONSORT Statement.
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colleagues [18] in a review of 63 cardiovascular trials
published between 2002 and 2004.
Study limitations
Our study has some limitations. First, we included only
reports of non-primary publications identified in PubMed
using the indexing term ‘Randomized Controlled Trial’.
We will therefore have missed some non-primary reports
that were not indexed using this term. The search was also
limited to the National Library of Medicine’s set of Core
Clinical Journals and so may not be representative of all
journals. Second, we included only reports of non-primary
publications which we identified as such from reading the
abstract or full text of the article, we did not assess the
trial protocol. Some non-primary publications may have
been omitted where the distinction was not clear (that
is, we identified them as primary reports) or where the
authors changed the nature of the outcome from that
specified in the protocol. For example Chan and col-
leagues [6] in a review of 102 reports of randomized
trials, identified major discrepancies in the specification of
outcomes when comparing the trial protocol with the
published article. Given the limitations of our approach to
this study, it is possible that we have underestimated the
number of non-primary publications and the magnitude
of the problem of poor reporting.
Implications for practice
The CONSORT Statement, most recently updated in
2010, provides recommendations for reporting the find-
ings of randomized trials [2]. While primarily aimed at
reporting the primary results, it also gives some recom-
mendations for when and how secondary outcomes and
additional subgroup analyses should be reported within
the context of the primary publication. We are not
aware of any specific reporting guidelines for addressing
non-primary reports of randomized trials (www.equator-
network.org). In response to our findings, we identified
some additional suggestions for what authors should de-
scribe when reporting these types of analyses in non-
primary reports of randomized trials (see Table 5).
In particular, authors should make clear in the abstract
that it is not the primary publication for the trial and
whether the analyses being reported were pre-specified
or exploratory analyses. In the full text of the article, au-
thors should specify the objectives or hypotheses being
tested for example whether reporting subgroup analyses,
secondary outcomes, or extended follow-up, and the
time point at which they are being assessed. It is also
important to set the study objectives within the context
of the main trial, giving details of the number of study
groups, the interventions, key aspects of trial method-
ology including the method of randomization, and the
primary outcome and its numerical results. Other
important information includes the number of partici-
pants in each group and whether the non-primary publi-
cation analyzed all, or a subset, of randomized
participants. The number of outcomes assessed in the
non-primary publication, whether each analysis was pre-
specified or exploratory, and the statistical methods used
to compare groups should be reported. As in the main
report, for each analysis authors should report a result
for each group and the estimated effect size and preci-
sion. Details of trial registration and the trial protocol
are also important to help readers have greater under-
standing of what was planned and what was done, and
to assess the validity and reliability of the new findings
within context of main randomized trial.
Conclusion
Based on the findings from our study, it is clear that
non-primary publications often lack important informa-
tion about the randomized trial, the type of analyses
conducted and whether these analyses were pre-specified
or exploratory. Without such key information, it is diffi-
cult for readers to accurately identify such non-primary
trial reports and to assess the validity and reliably of the
study results. In response to our findings, we provide rec-
ommendations for what information authors should in-
clude in non-primary reports of randomized trials.
Additional file
Additional file 1: Examples of different types of analysisa reported
in the non-primary publication.
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